Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 6/20 | 0.76 |
| ▸ | DGKZ | Q13574 | 5/20 | 0.76 |
| ▸ | DGKI | O75912 | 3/20 | 0.76 |
| ▸ | DGKG | P49619 | 2/20 | 0.76 |
| ▸ | DGKB | Q9Y6T7 | 2/20 | 0.76 |
| ▸ | DGKK | Q5KSL6 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29898584 | 1.00 | DGKA (0.76) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293465 | 0.91 | DGKA (0.64) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293356 | 0.91 | DGKA (0.64) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293331 | 0.90 | DGKA (0.71) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL30422088 | 0.90 | DGKA (0.63) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293206 | 0.90 | DGKA (0.63) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293124 | 0.90 | DGKA (0.63) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293405 | 0.89 | DGKA (0.62) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293149 | 0.89 | DGKA (0.62) | DGKADGKZDGKIDGKGDGKB | |
| SCHEMBL23293128 | 0.89 | DGKA (0.62) | DGKADGKZDGKIDGKGDGKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-09 | — | — | US | claimed |
| EP-3814347-B1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-03 | — | — | EP | claimed |
| US-20210277004-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-09 | — | — | US | claimed |
| EP-3814347-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | claimed |
| CN-112585139-A | Nalidinone compounds as T cell activators | 百时美施贵宝公司 | 2021-03-30 | — | — | CN | claimed |
| US-20240108654-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | JUNO THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2024054944-A1 | COMBINATION OF A T CELL THERAPY AND CONTINUOUS OR INTERMITTENT DGK INHIBITOR DOSING | JUNO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| CN-117693508-A | Combination of T cell therapy and DGK inhibitors | 朱诺治疗学股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4301755-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | Juno Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-09 | — | — | US | disclosed |
| CN-112585139-B | Naphthyridinone compounds as T cell activators | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-3814347-B1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20230089255-A1 | COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-03-23 | — | — | US | disclosed |
| CN-115243721-A | Combination of DGK inhibitors and checkpoint antagonists | 百时美施贵宝公司 | 2022-10-25 | — | — | CN | disclosed |
| US-20210277004-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-09 | — | — | US | disclosed |
| US-20210277004-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-09 | — | — | US | disclosed |
| WO-2021127554-A1 | COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3814347-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-112585139-A | Nalidinone compounds as T cell activators | 百时美施贵宝公司 | 2021-03-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | DGKA 2/4885DGKZ 1/4885DGKI 6/4885 |
| US-20210277004-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | DGKA 2/4885DGKZ 1/4885DGKI 6/4885 |
| US-20240108654-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | DGKG, DGKA, DGKI | DGKA 2/4885DGKZ 6/4885DGKI 3/4885 |
| US-20230089255-A1 | COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS | DGKA, DGKG, DGKB | DGKA 1/4885DGKZ 9/4885DGKI 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.